The Neuro-Immune-Barrier Axis in Atopic Dermatitis: Pathophysiologic Insights and Targeted Therapeutic Breakthroughs
Adolescência e Saúde · 04.10.2026 · 3727-3739
DOI: 10.67440/ahj.vi.2968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Adolescência e Saúde, online erschienen am 04.10.2026. Verfasst von Bhujithra M und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atopic dermatitis (AD) is an inflammatory skin condition that lasts for a long time and causes the skin's protective barrier to break down, leading to immune dysregulation and constant itching. In this review, we look at the neuro-immune-barrier axis that is involved in the development of Atopic dermatitis (AD), specifically at abnormalities in the barrier, type 2 inflammation, microbial dysbiosis, and neuronal sensitization. Flaws in filaggrin, epidermal lipids, and tight junctions elevate transepidermal water loss and promote allergen infiltration. Epithelial alarmins facilitate type 2 immune responses, especially through interleukin (IL)-4 and IL-13, whereas IL-31 and additional neuroimmune factors play a role in persistent pruritus and the itch-scratch cycle. The proliferation of Staphylococcus aureus intensifies inflammation and compromises barrier integrity. Targeted treatments, such as biologics and Janus kinase inhibitors, have enhanced disease management; nevertheless, ongoing pruritus, inconsistent treatment outcomes, and long-term safety issues persist. Innovative approaches, including aryl hydrocarbon receptor agonists, OX40/OX40L-targeted treatments, microbiome-centric interventions, and biomarker-driven precision medicine, could present novel therapeutic avenues. Improving long-term disease control and patient quality of life and supporting the development of personalized treatments could be achieved by understanding the interactions between neural, immune, microbial, and epidermal components.
Zitieren
APA
M, B., S, S. P., & R, K. (2026). The Neuro-Immune-Barrier Axis in Atopic Dermatitis: Pathophysiologic Insights and Targeted Therapeutic Breakthroughs. Adolescência e Saúde, 3727-3739. https://doi.org/10.67440/ahj.vi.2968
Vancouver
M B, S SP, R K. The Neuro-Immune-Barrier Axis in Atopic Dermatitis: Pathophysiologic Insights and Targeted Therapeutic Breakthroughs. Adolescência e Saúde. 2026:3727-3739. doi:10.67440/ahj.vi.2968
BibTeX
@article{M2026,
author = {M, Bhujithra and S, Sakthi Priyadarsini and R, Kamaraj},
title = {The Neuro-Immune-Barrier Axis in Atopic Dermatitis: Pathophysiologic Insights and Targeted Therapeutic Breakthroughs},
journal = {Adolescência e Saúde},
year = {2026},
pages = {3727--3739},
doi = {10.67440/ahj.vi.2968}
}
EUVIMED